Our study aims to assess the effects of the CYP3A4*22 allele and CYP3A5 expressor status in ticagrelor treated patients with a myocardial infarction, with respect to clinical endpoints and the most common side-effect dyspnea. This evidence concerns the gene CYP3A5 and myocardial infarction.